Get the Stockscreener App
4.99
17.97%
0.76
After Hours:
4.97
-0.02
-0.40%
Galectin Therapeutics Inc stock is traded at $4.99, with a volume of 6.47M.
It is up +17.97% in the last 24 hours and up +78.85% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$4.23
Open:
$4.18
24h Volume:
6.47M
Relative Volume:
12.53
Market Cap:
$328.63M
Revenue:
-
Net Income/Loss:
$-26.25M
P/E Ratio:
-12.17
EPS:
-0.4099
Net Cash Flow:
$-20.05M
1W Performance:
+76.64%
1M Performance:
+78.85%
6M Performance:
+23.21%
1Y Performance:
+112.34%
1-Day Range:
$4.18
$5.025
1-Week Range:
$2.71
$5.025
52-Week Range:
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.99 | 328.63M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
GALT jumps 11% on FDA alignment for belapectin phase III path in MASH - MSN
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
Form 144 GALECTIN THERAPEUTICS INC For: 26 June - Investing.com UK
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com - Investing.com Nigeria
GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals - Stock Titan
Form 144 GALECTIN THERAPEUTICS INCORPORATED For: 26 June By Investing.com - Investing.com Canada
[144] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
Galectin Therapeutics Inc. Actuals & Estimates (FWB:PHPN) - TradingView
GALT Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares - Investing.com
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares By Investing.com - Investing.com Australia
Form 4 Galectin Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan - Stock Titan
PHPN Forecast — Price Target — Prediction for 2027 - TradingView
FDA alignment reduces risk for Galectin Therapeutics' belapectin Phase 3 trial, keeping it a buy. - Pluang
Galectin De-Risks Belapectin Path With FDA AlignmentSets Stage For Phase 3 Upside - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH - The Globe and Mail
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Form 144 GALECTIN THERAPEUTICS INC For: 23 June By Investing.com - Investing.com Australia
Form 144 GALECTIN THERAPEUTICS INC For: 23 June - Investing.com UK
GALT affiliate notifies sale of 8,125 shares (NASDAQ: GALT) - Stock Titan
Galectin Therapeutics (GALT) Announces FDA Agreement for Phase 3 Program - GuruFocus
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Asianet Newsable
Galectin reaches FDA agreement on Phase 3 trial for belapectin By Investing.com - Investing.com South Africa
Galectin Therapeutics stock surges on FDA trial agreement - Investing.com
Galectin Therapeutics stock surges on FDA trial agreement By Investing.com - Investing.com South Africa
Galectin Therapeutics clears FDA Type C milestone, shares react on NASDAQ - Ad-hoc-news.de
GALT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $11 - GuruFocus
Form 8K Galectin Therapeutics Inc For: 23 June By Investing.com - Investing.com India
Galectin Therapeutics (GALT) Receives FDA Feedback for Phase 3 T - GuruFocus
Galectin Therapeutics Shares Surge on Positive FDA Meeting, Phase 3 Trial Plans - marketscreener.com
Galectin Therapeutics (GALT) Receives FDA Feedback for Phase 3 Trial Preparation - GuruFocus
Galectin reaches FDA agreement on Phase 3 trial for belapectin - Investing.com
Galecti, FDA agree on Phase 3 trial for MASH drug (GALT:NASDAQ) - Seeking Alpha
Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial - marketscreener.com
Galectin Therapeutics Secures FDA Agreement for Phase 3 Belapectin Trial in MASH Cirrhosis and Portal Hypertension 1 – Minichart - Minichart
Galectin Advances Belapectin to Phase 3 After FDA Alignment - TipRanks
Galectin Therapeutics Reaches FDA Agreement on Phase 3 Endpoint and Regulatory Path for Belapectin Full Approval - Quiver Quantitative
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension - Yahoo Finance
Galectin Announces FDA Agreement on Phase 3 Endpoint and Q3 2026 Protocol Filing for Belapectin - TradingView
FDA backs Galectin (NASDAQ: GALT) belapectin Phase 3 plan in MASH - Stock Titan
GALT Stock Surges 22%On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Mena FN
Galectin Therapeutics Inc (GALT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galectin Therapeutics Inc (GALT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):